285 related articles for article (PubMed ID: 28072764)
41. Gene mutations differently impact the prognosis of the myelodysplastic and myeloproliferative classes of chronic myelomonocytic leukemia.
Cervera N; Itzykson R; Coppin E; Prebet T; Murati A; Legall S; Vey N; Solary E; Birnbaum D; Gelsi-Boyer V
Am J Hematol; 2014 Jun; 89(6):604-9. PubMed ID: 24595958
[TBL] [Abstract][Full Text] [Related]
42. A systems biology approach to characterize the regulatory networks leading to trabectedin resistance in an in vitro model of myxoid liposarcoma.
Uboldi S; Calura E; Beltrame L; Fuso Nerini I; Marchini S; Cavalieri D; Erba E; Chiorino G; Ostano P; D'Angelo D; D'Incalci M; Romualdi C
PLoS One; 2012; 7(4):e35423. PubMed ID: 22523595
[TBL] [Abstract][Full Text] [Related]
43. Trabectedin has promising antineoplastic activity in high-grade meningioma.
Preusser M; Spiegl-Kreinecker S; Lötsch D; Wöhrer A; Schmook M; Dieckmann K; Saringer W; Marosi C; Berger W
Cancer; 2012 Oct; 118(20):5038-49. PubMed ID: 22392434
[TBL] [Abstract][Full Text] [Related]
44. Ascites interferes with the activity of lurbinectedin and trabectedin: Potential role of their binding to alpha 1-acid glycoprotein.
Erba E; Romano M; Gobbi M; Zucchetti M; Ferrari M; Matteo C; Panini N; Colmegna B; Caratti G; Porcu L; Fruscio R; Perlangeli MV; Mezzanzanica D; Lorusso D; Raspagliesi F; D'Incalci M
Biochem Pharmacol; 2017 Nov; 144():52-62. PubMed ID: 28782526
[TBL] [Abstract][Full Text] [Related]
45. Trabectedin in soft tissue sarcomas.
Petek BJ; Loggers ET; Pollack SM; Jones RL
Mar Drugs; 2015 Feb; 13(2):974-83. PubMed ID: 25686274
[TBL] [Abstract][Full Text] [Related]
46. Role of cedazuridine/decitabine in the management of myelodysplastic syndrome and chronic myelomonocytic leukemia.
Thota S; Oganesian A; Azab M; Griffiths EA
Future Oncol; 2021 Jun; 17(16):2077-2087. PubMed ID: 33709786
[TBL] [Abstract][Full Text] [Related]
47. Trabectedin mechanism of action and platinum resistance: molecular rationale.
Ray-Coquard I
Future Oncol; 2017 Oct; 13(23s):17-21. PubMed ID: 29020822
[TBL] [Abstract][Full Text] [Related]
48. Trabectedin in ovarian cancer: could we expect more?
Sessa C; D'Incalci M
Ann Oncol; 2011 Jan; 22(1):7-8. PubMed ID: 21059638
[No Abstract] [Full Text] [Related]
49. Azacitidine for the treatment of myelodysplastic syndrome, chronic myelomonocytic leukaemia and acute myeloid leukaemia.
Edlin R; Connock M; Tubeuf S; Round J; Fry-Smith A; Hyde C; Greenheld W
Health Technol Assess; 2010 May; 14 Suppl 1():69-74. PubMed ID: 20507806
[TBL] [Abstract][Full Text] [Related]
50. Trabectedin for the management of soft-tissue sarcoma.
Boudou L; Baconnier M; Blay JY; Lombard-Bohas C; Cassier PA
Expert Rev Anticancer Ther; 2009 Jun; 9(6):727-37. PubMed ID: 19496709
[TBL] [Abstract][Full Text] [Related]
51. Trabectedin mechanism of action: what's new?
D'Incalci M
Future Oncol; 2013 Dec; 9(12 Suppl):5-10. PubMed ID: 24195524
[TBL] [Abstract][Full Text] [Related]
52. Juvenile myelomonocytic leukemia.
Proytcheva M
Semin Diagn Pathol; 2011 Nov; 28(4):298-303. PubMed ID: 22195407
[TBL] [Abstract][Full Text] [Related]
53. Biology of ovarian cancer and trabectedin mechanism of action.
Ray-Coquard I
Future Oncol; 2013 Dec; 9(12 Suppl):11-7. PubMed ID: 24195525
[TBL] [Abstract][Full Text] [Related]
54. Myelodysplastic/myeloproliferative neoplasms - Justified inclusion as unique biological entities.
Patnaik MM
Best Pract Res Clin Haematol; 2020 Jun; 33(2):101135. PubMed ID: 32460978
[No Abstract] [Full Text] [Related]
55. CMML: Clinical and molecular aspects.
Itzykson R; Duchmann M; Lucas N; Solary E
Int J Hematol; 2017 Jun; 105(6):711-719. PubMed ID: 28455647
[TBL] [Abstract][Full Text] [Related]
56. Molecular pathogenesis of atypical CML, CMML and MDS/MPN-unclassifiable.
Zoi K; Cross NC
Int J Hematol; 2015 Mar; 101(3):229-42. PubMed ID: 25212680
[TBL] [Abstract][Full Text] [Related]
57. Biological Activities of RUNX1 Mutants Predict Secondary Acute Leukemia Transformation from Chronic Myelomonocytic Leukemia and Myelodysplastic Syndromes.
Tsai SC; Shih LY; Liang ST; Huang YJ; Kuo MC; Huang CF; Shih YS; Lin TH; Chiu MC; Liang DC
Clin Cancer Res; 2015 Aug; 21(15):3541-51. PubMed ID: 25840971
[TBL] [Abstract][Full Text] [Related]
58. Activity of trabectedin and the PARP inhibitor rucaparib in soft-tissue sarcomas.
Laroche A; Chaire V; Le Loarer F; Algéo MP; Rey C; Tran K; Lucchesi C; Italiano A
J Hematol Oncol; 2017 Apr; 10(1):84. PubMed ID: 28399901
[TBL] [Abstract][Full Text] [Related]
59. Novel therapeutic targets for chronic myelomonocytic leukemia.
Lasho T; Patnaik MM
Best Pract Res Clin Haematol; 2021 Mar; 34(1):101244. PubMed ID: 33762099
[TBL] [Abstract][Full Text] [Related]
60. Trabectedin for Soft Tissue Sarcoma: Current Status and Future Perspectives.
Gordon EM; Sankhala KK; Chawla N; Chawla SP
Adv Ther; 2016 Jul; 33(7):1055-71. PubMed ID: 27234989
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]